CoChat

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS‐mutant melanoma

Open access
Rebecca, Vito W., Alicea, Gretchen M., Paraiso, Kim H. T., Lawrence, Harshani, Gibney, Geoffrey T., Smalley, Keiran S. M. · 2014 · Pigment Cell & Melanoma Research
Cited by 53

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Summary: The MEK inhibitor MEK 162 is the first targeted therapy agent with clinical activity in patients whose melanomas harbor NRAS mutations; however, median PFS is 3.7 months, suggesting the rapid onset of resistance in the majority of patients. Here, we show that treatment of NRAS‐mutant melanoma cell lines with the MEK inhibitors AZD 6244 or trametinib resulted in a rebound activation of phospho‐ERK (p ERK). Functionally, the recovery of signaling was associated with the maintenance of cyclin‐D 1 expression and therapeutic escape. The combination of a MEK inhibitor with an ERK inhibitor suppressed the recovery of cyclin‐D 1 expression and was associated with a significant enhancement of apoptosis and the abrogation of clonal outgrowth. The MEK/ERK combination strategy induced greater levels of apoptosis compared with dual MEK/CDK 4 or MEK/PI3K inhibition across a panel of cell lines. These data provide the rationale for further investigation of vertically co‐targeting the MAPK pathway as a potential treatment option for NRAS‐mutant melanoma patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/pcmr.12303

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 53

Metadata

Authors
Rebecca, V. W., Alicea, G. M., Paraiso, K. H. T., Lawrence, H., Gibney, G. T., & Smalley, K. S. M.
Venue
Pigment Cell & Melanoma Research
Publisher
Wiley
Published
2014-09
Volume
27
Issue
6
Pages
1154-1158
ISSN
  • 1755-1471 (ISSN-L)
  • 1755-148X
OpenAlex
W2153681526
Cited by
53
References
9
FWCI
2.80
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS‐mutant melanoma. https://app.cochat.ai/papers/10.1111/pcmr.12303
The paper
Rebecca, V. W., Alicea, G. M., Paraiso, K. H. T., Lawrence, H., Gibney, G. T., & Smalley, K. S. M. (2014). Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS‐mutant melanoma. Pigment Cell & Melanoma Research. https://doi.org/10.1111/pcmr.12303

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.